首页 > 最新文献

Diabetes & Vascular Disease Research最新文献

英文 中文
Impact of COVID-19 therapy on hyperglycemia COVID-19治疗对高血糖的影响
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-05-01 DOI: 10.1177/14791641221095091
Rachel Parise, J. Deruiter, Jun Ren, Manoj Govindarajulu, S. Ramesh, Rishi M. Nadar, Timothy Moore, M. Dhanasekaran
The goal of this study was to analyze the effect of COVID-19 drugs and biologicals on hyperglycemia. A literature search with key terms, such as “COVID-19 drugs and hyperglycemia” and “COVID-19 vaccines and hyperglycemia,” was conducted using PubMed through September 2021. The CDC data were referenced for current COVID-19 profile and statistics. The NIH COVID-19 guidelines were referenced for updated treatment recommendations. Micromedex and UpToDate were used for drug and disease information. Current results suggested that corticosteroids (dexamethasone), remdesivir and antivirals (lopinavir and ritonavir) all have the potential to significantly raise blood glucose levels putting patients at elevated risk for severe complications. In contrary, hydroxychloroquine is associated with hypoglycemia, and tocilizumab decreases inflammation which is associated with improving glucose levels. Other anti-cytokine bioactive molecules are correlated with lower blood glucose in patients with and without diabetes mellitus. Ivermectin, used for mild COVID-19 disease, possesses the potential for lowering blood glucose. Covishield, Pfizer-BioNTech, and Moderna have all been associated with hyperglycemia after the first dose. Individualized /personalized patient care is required for diabetic mellitus patients with COVID-19 infection. Improper drug therapy aggravates hyperglycemic conditions and other comorbid conditions, leading to increased morbidity and mortality.
本研究的目的是分析COVID-19药物和生物制剂对高血糖的影响。截止到2021年9月,在PubMed上以“COVID-19药物和高血糖”、“COVID-19疫苗和高血糖”等关键词进行了文献检索。参考疾病预防控制中心的数据进行当前COVID-19概况和统计。更新的治疗建议参考了美国国立卫生研究院COVID-19指南。使用Micromedex和UpToDate获取药物和疾病信息。目前的结果表明,皮质类固醇(地塞米松)、瑞德西韦和抗病毒药物(洛匹那韦和利托那韦)都有可能显著提高血糖水平,使患者面临严重并发症的风险增加。相反,羟氯喹与低血糖有关,而托珠单抗可以减少炎症,从而改善血糖水平。其他抗细胞因子生物活性分子与糖尿病患者和非糖尿病患者的低血糖相关。用于治疗COVID-19轻度疾病的伊维菌素具有降低血糖的潜力。Covishield, Pfizer-BioNTech和Moderna在首次服用后都与高血糖有关。糖尿病合并COVID-19感染患者需要个性化/个性化患者护理。不适当的药物治疗加重了高血糖状况和其他合并症,导致发病率和死亡率增加。
{"title":"Impact of COVID-19 therapy on hyperglycemia","authors":"Rachel Parise, J. Deruiter, Jun Ren, Manoj Govindarajulu, S. Ramesh, Rishi M. Nadar, Timothy Moore, M. Dhanasekaran","doi":"10.1177/14791641221095091","DOIUrl":"https://doi.org/10.1177/14791641221095091","url":null,"abstract":"The goal of this study was to analyze the effect of COVID-19 drugs and biologicals on hyperglycemia. A literature search with key terms, such as “COVID-19 drugs and hyperglycemia” and “COVID-19 vaccines and hyperglycemia,” was conducted using PubMed through September 2021. The CDC data were referenced for current COVID-19 profile and statistics. The NIH COVID-19 guidelines were referenced for updated treatment recommendations. Micromedex and UpToDate were used for drug and disease information. Current results suggested that corticosteroids (dexamethasone), remdesivir and antivirals (lopinavir and ritonavir) all have the potential to significantly raise blood glucose levels putting patients at elevated risk for severe complications. In contrary, hydroxychloroquine is associated with hypoglycemia, and tocilizumab decreases inflammation which is associated with improving glucose levels. Other anti-cytokine bioactive molecules are correlated with lower blood glucose in patients with and without diabetes mellitus. Ivermectin, used for mild COVID-19 disease, possesses the potential for lowering blood glucose. Covishield, Pfizer-BioNTech, and Moderna have all been associated with hyperglycemia after the first dose. Individualized /personalized patient care is required for diabetic mellitus patients with COVID-19 infection. Improper drug therapy aggravates hyperglycemic conditions and other comorbid conditions, leading to increased morbidity and mortality.","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45959928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Sleep behaviours and associated habits and the progression of pre-diabetes to type 2 diabetes mellitus in adults: A systematic review and meta-analysis 睡眠行为和相关习惯与成人糖尿病前期到2型糖尿病的进展:一项系统回顾和荟萃分析
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-05-01 DOI: 10.1177/14791641221088824
S. Mostafa, S. Mena, C. Antza, G. Balanos, K. Nirantharakumar, A. Tahrani
Introduction Certain sleep behaviours increase risk of type 2 diabetes mellitus (T2DM) in the general population, but whether they contribute to the progression from pre-diabetes to T2DM is uncertain. We conducted a systematic review to assess this. Methods Structured searches were performed on bibliographic databases (MEDLINE, EMBASE and CINAHL) from inception to 26/04/2021 for longitudinal studies/trials consisting of adults⩾18 years with pre-diabetes and sleep behaviours (short or long sleep duration (SD), late chronotype, insomnia, obstructive sleep apnoea, daytime napping and/or night-shift employment) that reported on incident T2DM or glycaemic changes. The Newcastle-Ottawa Scale was used for quality assessment. Results Six studies were included. Meta-analysis of three studies (n = 20,139) demonstrated that short SD was associated with greater risk of progression to T2DM, hazard ratio (HR) 1.59 (95% CI 1.29-1.97), I2 heterogeneity score 0%, p < 0.0001, but not for long SD, HR 1.50 (0.86–2.62), I2 heterogeneity 77%, p = 0.15. The systematic review showed insomnia and night-shift duty were associated with higher progression to T2DM. Studies were rated as moderate-to-high quality. Conclusions Progression from pre-diabetes to T2DM increases with short SD, but only limited data exists for insomnia and night-shift duty. Whether manipulating sleep could reduce progression from pre-diabetes to T2DM needs to be examined.
引言某些睡眠行为会增加普通人群患2型糖尿病(T2DM)的风险,但它们是否会导致糖尿病前期向T2DM的进展尚不确定。我们对此进行了系统的审查。方法从一开始到2021年4月26日,在书目数据库(MEDLINE、EMBASE和CINAHL)上进行结构化搜索,以进行纵向研究/试验,这些研究/试验由患有糖尿病前期和睡眠行为(睡眠时间短或长(SD)、晚型、失眠、阻塞性睡眠呼吸暂停、,白天打盹和/或夜班工作),其报告了T2DM事件或血糖变化。纽卡斯尔-渥太华量表用于质量评估。结果纳入6项研究。对三项研究(n=20139)的荟萃分析表明,短SD与更大的进展为T2DM的风险相关,危险比(HR)1.59(95%CI 1.29-1.97),I2异质性得分0%,p<0.0001,但与长SD无关,HR 1.50(0.86-2.62),I2-异质性77%,p=0.15。系统综述显示,失眠和上夜班与更高的T2DM进展有关。研究被评为中等至高质量。结论从糖尿病前期到T2DM的进展随着SD的缩短而增加,但失眠和夜班的数据有限。控制睡眠是否可以减少从糖尿病前期到T2DM的进展,还有待研究。
{"title":"Sleep behaviours and associated habits and the progression of pre-diabetes to type 2 diabetes mellitus in adults: A systematic review and meta-analysis","authors":"S. Mostafa, S. Mena, C. Antza, G. Balanos, K. Nirantharakumar, A. Tahrani","doi":"10.1177/14791641221088824","DOIUrl":"https://doi.org/10.1177/14791641221088824","url":null,"abstract":"Introduction Certain sleep behaviours increase risk of type 2 diabetes mellitus (T2DM) in the general population, but whether they contribute to the progression from pre-diabetes to T2DM is uncertain. We conducted a systematic review to assess this. Methods Structured searches were performed on bibliographic databases (MEDLINE, EMBASE and CINAHL) from inception to 26/04/2021 for longitudinal studies/trials consisting of adults⩾18 years with pre-diabetes and sleep behaviours (short or long sleep duration (SD), late chronotype, insomnia, obstructive sleep apnoea, daytime napping and/or night-shift employment) that reported on incident T2DM or glycaemic changes. The Newcastle-Ottawa Scale was used for quality assessment. Results Six studies were included. Meta-analysis of three studies (n = 20,139) demonstrated that short SD was associated with greater risk of progression to T2DM, hazard ratio (HR) 1.59 (95% CI 1.29-1.97), I2 heterogeneity score 0%, p < 0.0001, but not for long SD, HR 1.50 (0.86–2.62), I2 heterogeneity 77%, p = 0.15. The systematic review showed insomnia and night-shift duty were associated with higher progression to T2DM. Studies were rated as moderate-to-high quality. Conclusions Progression from pre-diabetes to T2DM increases with short SD, but only limited data exists for insomnia and night-shift duty. Whether manipulating sleep could reduce progression from pre-diabetes to T2DM needs to be examined.","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42662389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Ultra-high frequency ultrasound delineated changes in carotid and muscular artery intima-media and adventitia thickness in obese early middle-aged women 超高频超声描绘了肥胖中年早期妇女颈动脉和肌肉动脉内膜-中膜和外膜厚度的变化
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-05-01 DOI: 10.1177/14791641221094321
J. Sundholm, L. Litwin, K. Rönö, S. Koivusalo, J. Eriksson, T. Sarkola
Obesity is linked to increased arterial size, carotid intima-media thickness and arterial stiffness. The effects of obesity and body composition on muscular artery intima-media and adventitia thickness has previously not been established. The aim of this study was to explore associations between carotid and muscular artery wall layer thickness with body composition and cardiovascular risk factors in early middle-aged women. This is a cross-sectional study including 199 women aged 40±4 years. Arterial lumen (LD), intima-media (IMT) and adventitia thickness (AT) were measured from carotid, brachial and radial arteries using ultra-high frequency ultrasound (22-71 MHz). Women with obesity had increased IMT in carotid (0.47 vs 0.45 mm), brachial (0.19 vs 0.17 mm) and radial arteries (0.16 vs 0.15 mm) and increased brachial AT (0.14 vs 0.13 mm). In multiple regression models all arterial LD (β-range 0.02-0.03 mm/kg/m2), IMT (β-range 0.91-3.37 µm/kg/m2), AT (β-range 0.73-1.38 µm/kg/m2) were significantly associated with BMI. The IMT of all arteries were significantly associated with systolic blood pressure (β-range 0.36-0.85 µm/mmHg), attenuating the association between IMT and BMI (β-range 0.18-2.24 µm/kg/m2). Obese early middle-aged women have increased arterial intima media thickness and brachial artery adventitia thickness compared to non-obese counterparts. The association between BMI and intima-media thickness is partly mediated through blood pressure levels.
肥胖与动脉大小、颈动脉内膜中层厚度和动脉硬化有关。肥胖和身体成分对肌动脉内膜-中膜和外膜厚度的影响以前尚未确定。本研究的目的是探讨中年早期女性颈动脉和肌肉动脉壁层厚度与身体成分和心血管危险因素之间的关系。这是一项横断面研究,包括199名年龄为40±4岁的女性。使用超高频超声(22-71MHz)测量颈动脉、肱动脉和桡动脉的动脉管腔(LD)、内膜-中层(IMT)和外膜厚度(AT)。肥胖女性颈动脉(0.47 vs 0.45 mm)、肱动脉(0.19 vs 0.17 mm)和桡动脉(0.16 vs 0.15 mm)的IMT增加,肱动脉AT增加(0.14 vs 0.13 mm)。在多元回归模型中,所有动脉LD(β范围0.02-0.03 mm/kg/m2)、IMT(β范围0.91-3.37µm/kg/m2)和AT(β范围0.73-1.38µm/kg/m 2)均与BMI显著相关。所有动脉的IMT与收缩压显著相关(β-范围0.36-0.85µm/mmHg),减弱了IMT与BMI之间的相关性(β-范围0.18-2.24µm/kg/m2)。与非肥胖女性相比,肥胖的中早期女性动脉内膜-中膜厚度和肱动脉外膜厚度增加。BMI和内膜-中层厚度之间的联系部分是通过血压水平介导的。
{"title":"Ultra-high frequency ultrasound delineated changes in carotid and muscular artery intima-media and adventitia thickness in obese early middle-aged women","authors":"J. Sundholm, L. Litwin, K. Rönö, S. Koivusalo, J. Eriksson, T. Sarkola","doi":"10.1177/14791641221094321","DOIUrl":"https://doi.org/10.1177/14791641221094321","url":null,"abstract":"Obesity is linked to increased arterial size, carotid intima-media thickness and arterial stiffness. The effects of obesity and body composition on muscular artery intima-media and adventitia thickness has previously not been established. The aim of this study was to explore associations between carotid and muscular artery wall layer thickness with body composition and cardiovascular risk factors in early middle-aged women. This is a cross-sectional study including 199 women aged 40±4 years. Arterial lumen (LD), intima-media (IMT) and adventitia thickness (AT) were measured from carotid, brachial and radial arteries using ultra-high frequency ultrasound (22-71 MHz). Women with obesity had increased IMT in carotid (0.47 vs 0.45 mm), brachial (0.19 vs 0.17 mm) and radial arteries (0.16 vs 0.15 mm) and increased brachial AT (0.14 vs 0.13 mm). In multiple regression models all arterial LD (β-range 0.02-0.03 mm/kg/m2), IMT (β-range 0.91-3.37 µm/kg/m2), AT (β-range 0.73-1.38 µm/kg/m2) were significantly associated with BMI. The IMT of all arteries were significantly associated with systolic blood pressure (β-range 0.36-0.85 µm/mmHg), attenuating the association between IMT and BMI (β-range 0.18-2.24 µm/kg/m2). Obese early middle-aged women have increased arterial intima media thickness and brachial artery adventitia thickness compared to non-obese counterparts. The association between BMI and intima-media thickness is partly mediated through blood pressure levels.","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41825639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study. 钠-葡萄糖共转运蛋白2抑制剂与痴呆发生率之间的关系:一项基于全国人群的纵向队列研究。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-05-01 DOI: 10.1177/14791641221098168
Wun-Zhih Siao, Tsung-Kun Lin, Jing-Yang Huang, Chin-Feng Tsai, Gwo-Ping Jong

Background: The association of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor and incident dementia remains unclear. This study aimed to evaluate the risk of incident dementia with the use of SGLT2 inhibitor.

Methods: This is a population-based cohort study utilizing Taiwan's National Health Insurance Research Database. Each patient who took SGLT2 inhibitors was assigned to the SGLT2 inhibitor group, whereas 1:1 propensity score-matched randomly selected patients who were nonusers of SGLT2 inhibitors were assigned to the non-SGLT2 inhibitor group. The study outcome was incident dementia.

Results: A total of 976,972 patients newly diagnosed with type 2 diabetes mellitus (DM) between 2011 and 2018 were included in this study. After the patients' propensity score matching by age, sex, duration of DM, comorbidities and drug index date of the patients, a total of 103,247 patients in the SGLT2 inhibitor group and 103,247 in the non-SGLT2 inhibitor group were enrolled for analysis. The SGLT2 inhibitor group was associated with a lower risk of incident dementia (adjusted hazard ratio: 0.89, 95% confidence interval: 0.82-0.96; p = .0021). Diabetic complications were significantly lower in the SGLT2 inhibitor group compared with the non-SGLT2 group. Sensitivity analysis was also consistent with the main analysis.

Conclusions: Patients with type 2 DM who were prescribed SGLT2 inhibitors were associated with a lower risk of incident dementia compared with those not prescribed SGLT2 inhibitors in real-world practice.

背景:钠-葡萄糖共转运蛋白2 (SGLT2)抑制剂的使用与痴呆的发生之间的关系尚不清楚。本研究旨在评估使用SGLT2抑制剂后发生痴呆的风险。方法:本研究以人群为基础,利用台湾全民健康保险研究数据库进行队列研究。每个服用SGLT2抑制剂的患者被分配到SGLT2抑制剂组,而1:1倾向评分匹配的随机选择的非SGLT2抑制剂的患者被分配到非SGLT2抑制剂组。研究结果为偶发性痴呆。结果:2011年至2018年共纳入976,972例新诊断为2型糖尿病(DM)的患者。将患者的年龄、性别、糖尿病病程、合并症、药物指标日期等倾向性评分匹配后,纳入SGLT2抑制剂组103247例患者和非SGLT2抑制剂组103247例患者进行分析。SGLT2抑制剂组发生痴呆的风险较低(校正风险比:0.89,95%可信区间:0.82-0.96;P = .0021)。与非SGLT2组相比,SGLT2抑制剂组糖尿病并发症明显降低。敏感性分析与主分析结果一致。结论:在现实世界中,与未服用SGLT2抑制剂的患者相比,服用SGLT2抑制剂的2型糖尿病患者发生痴呆的风险较低。
{"title":"The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study.","authors":"Wun-Zhih Siao,&nbsp;Tsung-Kun Lin,&nbsp;Jing-Yang Huang,&nbsp;Chin-Feng Tsai,&nbsp;Gwo-Ping Jong","doi":"10.1177/14791641221098168","DOIUrl":"https://doi.org/10.1177/14791641221098168","url":null,"abstract":"<p><strong>Background: </strong>The association of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor and incident dementia remains unclear. This study aimed to evaluate the risk of incident dementia with the use of SGLT2 inhibitor.</p><p><strong>Methods: </strong>This is a population-based cohort study utilizing Taiwan's National Health Insurance Research Database. Each patient who took SGLT2 inhibitors was assigned to the SGLT2 inhibitor group, whereas 1:1 propensity score-matched randomly selected patients who were nonusers of SGLT2 inhibitors were assigned to the non-SGLT2 inhibitor group. The study outcome was incident dementia.</p><p><strong>Results: </strong>A total of 976,972 patients newly diagnosed with type 2 diabetes mellitus (DM) between 2011 and 2018 were included in this study. After the patients' propensity score matching by age, sex, duration of DM, comorbidities and drug index date of the patients, a total of 103,247 patients in the SGLT2 inhibitor group and 103,247 in the non-SGLT2 inhibitor group were enrolled for analysis. The SGLT2 inhibitor group was associated with a lower risk of incident dementia (adjusted hazard ratio: 0.89, 95% confidence interval: 0.82-0.96; <i>p</i> = .0021). Diabetic complications were significantly lower in the SGLT2 inhibitor group compared with the non-SGLT2 group. Sensitivity analysis was also consistent with the main analysis.</p><p><strong>Conclusions: </strong>Patients with type 2 DM who were prescribed SGLT2 inhibitors were associated with a lower risk of incident dementia compared with those not prescribed SGLT2 inhibitors in real-world practice.</p>","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":"19 3","pages":"14791641221098168"},"PeriodicalIF":2.4,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/b7/10.1177_14791641221098168.PMC9109279.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10241705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment 血浆蛋白质组学揭示了利拉鲁肽治疗后2型糖尿病患者心脏代谢谱的改善
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-05-01 DOI: 10.1177/14791641221094322
A. Ekhzaimy, A. Masood, H. Benabdelkamel, Tasnem Elhassan, M. Musambil, A. Alfadda
Background Diabetes mellitus is a chronic multisystem disease with a high global prevalence, including in Saudi Arabia. The Glucagon-like Peptide (GLP-1) receptor agonist liraglutide is known to lower glucose levels, reduce weight and improve cardiovascular outcome. However, mechanisms underlying the benefits of liraglutide treatment in patients with type 2 diabetes mellitus (T2DM) remain unclear. Methods In the present study, a 2D-DIGE MALDI-TOF mass spectrometric approach combined with bioinformatics and network pathway analysis explore the plasma proteomic profile. The study involved 20 patients with T2DM with mean age of 54.4 ± 9.5 years and Hemoglobin A1c (HbA1c) between 8% and 11% (inclusive). Results A statistically significant change (p < .006) was observed in HbA1c with no significant changes in body weight, renal function, or markers of dyslipidemia post-treatment with liraglutide. 2 D-DIGE gel analysis identified significant changes (⩾1.5-fold change, Analysis of variance (ANOVA), p ⩽ 0.05) in 72 proteins, (62 down and 10 up) in liraglutide pre-treatment compared to the post-treatment state. Proteins identified in our study were found to regulate metabolic processes including acute phase response proteins, enzymes, apolipoproteins with involvement of the inflammatory signaling pathways, NF-κB, AKT, and p38 MAPK Conclusion Liraglutide treatment decreased levels of acute phase response that to reduce the systemic chronic inflammatory state and oxidative stress, and eventually improve the cardio-metabolic profile in these patients.
背景糖尿病是一种慢性多系统疾病,在全球范围内发病率很高,包括在沙特阿拉伯。已知胰高血糖素样肽(GLP-1)受体激动剂利拉鲁肽可降低血糖水平、减轻体重并改善心血管预后。然而,利拉鲁肽治疗2型糖尿病(T2DM)患者的潜在机制尚不清楚。方法采用2D-DIGE-MALDI-TOF质谱法,结合生物信息学和网络通路分析,对血浆蛋白质组学图谱进行研究。该研究涉及20名T2DM患者,平均年龄为54.4±9.5岁,血红蛋白A1c(HbA1c)在8%至11%(含)之间。结果利拉鲁肽治疗后,HbA1c发生统计学显著变化(p<.006),体重、肾功能或血脂异常标志物无显著变化。2 D-DIGE凝胶分析发现,与治疗后状态相比,利拉鲁肽治疗前72种蛋白质(62种下降和10种上升)发生了显著变化(1.5倍变化,方差分析(ANOVA),p⩽0.05)。我们研究中鉴定的蛋白质被发现可以调节代谢过程,包括急性期反应蛋白、酶、参与炎症信号通路的载脂蛋白、NF-κB、AKT和p38 MAPK。结论利拉鲁肽治疗降低了急性期反应水平,从而降低了系统慢性炎症状态和氧化应激,并最终改善这些患者的心脏代谢状况。
{"title":"Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment","authors":"A. Ekhzaimy, A. Masood, H. Benabdelkamel, Tasnem Elhassan, M. Musambil, A. Alfadda","doi":"10.1177/14791641221094322","DOIUrl":"https://doi.org/10.1177/14791641221094322","url":null,"abstract":"Background Diabetes mellitus is a chronic multisystem disease with a high global prevalence, including in Saudi Arabia. The Glucagon-like Peptide (GLP-1) receptor agonist liraglutide is known to lower glucose levels, reduce weight and improve cardiovascular outcome. However, mechanisms underlying the benefits of liraglutide treatment in patients with type 2 diabetes mellitus (T2DM) remain unclear. Methods In the present study, a 2D-DIGE MALDI-TOF mass spectrometric approach combined with bioinformatics and network pathway analysis explore the plasma proteomic profile. The study involved 20 patients with T2DM with mean age of 54.4 ± 9.5 years and Hemoglobin A1c (HbA1c) between 8% and 11% (inclusive). Results A statistically significant change (p < .006) was observed in HbA1c with no significant changes in body weight, renal function, or markers of dyslipidemia post-treatment with liraglutide. 2 D-DIGE gel analysis identified significant changes (⩾1.5-fold change, Analysis of variance (ANOVA), p ⩽ 0.05) in 72 proteins, (62 down and 10 up) in liraglutide pre-treatment compared to the post-treatment state. Proteins identified in our study were found to regulate metabolic processes including acute phase response proteins, enzymes, apolipoproteins with involvement of the inflammatory signaling pathways, NF-κB, AKT, and p38 MAPK Conclusion Liraglutide treatment decreased levels of acute phase response that to reduce the systemic chronic inflammatory state and oxidative stress, and eventually improve the cardio-metabolic profile in these patients.","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46155201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: An observational study 葡萄糖变异性与不良血管状况有关,但仅在1型糖尿病患者存在胰岛素抵抗的情况下:一项观察性研究
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-05-01 DOI: 10.1177/14791641221103217
N. Kietsiriroje, S. Pearson, L. O’Mahoney, D. West, R. Ariëns, R. Ajjan, M. Campbell
Aims/Hypothesis We hypothesised that the detrimental effect of high glucose variability (GV) in people with type 1 diabetes is mainly evident in those with concomitant insulin resistance. Methods We conducted secondary analyses on continuous glucose monitoring (CGM) using baseline observational data from three randomised controlled trials and assessed the relationship with established vascular markers. We used standard CGM summary statistics and principal component analysis to generate individual glucose variability signatures for each participant. Cluster analysis was then employed to establish three GV clusters (low, intermediate, or high GV, respectively). The relationship with thrombotic biomarkers was then investigated according to insulin resistance, assessed as estimated glucose disposal rate (eGDR). Results Of 107 patients, 45%, 37%, and 18% of patients were assigned into low, intermediate, and high GV clusters, respectively. Thrombosis biomarkers (including fibrinogen, plasminogen activator inhibitor-1, tissue factor activity, and tumour necrosis factor-alpha) increased in a stepwise fashion across all three GV clusters; this increase in thrombosis markers was evident in the presence of low but not high eGDR and at a threshold of eGDR <5.1 mg/kg/min. Conclusion Higher GV is associated with increased thrombotic biomarkers in type 1 diabetes but only in those with concomitant insulin resistance.
目的/假设我们假设高葡萄糖变异性(GV)对1型糖尿病患者的有害影响主要体现在伴有胰岛素抵抗的患者身上。方法利用3个随机对照试验的基线观察数据对连续血糖监测(CGM)进行二次分析,并评估其与血管标志物的关系。我们使用标准的CGM汇总统计和主成分分析来生成每个参与者的个体葡萄糖变异性特征。然后采用聚类分析建立三个GV聚类(分别为低、中、高GV)。然后根据胰岛素抵抗研究与血栓形成生物标志物的关系,评估估计葡萄糖处置率(eGDR)。结果在107例患者中,45%、37%和18%的患者分别被划分为低、中、高GV组。血栓形成生物标志物(包括纤维蛋白原、纤溶酶原激活物抑制剂-1、组织因子活性和肿瘤坏死因子- α)在所有三个GV簇中均呈逐步上升趋势;这种血栓标志物的增加在eGDR低但不高以及eGDR <5.1 mg/kg/min时表现明显。结论高GV与1型糖尿病患者血栓形成生物标志物升高相关,但仅与伴有胰岛素抵抗的患者相关。
{"title":"Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: An observational study","authors":"N. Kietsiriroje, S. Pearson, L. O’Mahoney, D. West, R. Ariëns, R. Ajjan, M. Campbell","doi":"10.1177/14791641221103217","DOIUrl":"https://doi.org/10.1177/14791641221103217","url":null,"abstract":"Aims/Hypothesis We hypothesised that the detrimental effect of high glucose variability (GV) in people with type 1 diabetes is mainly evident in those with concomitant insulin resistance. Methods We conducted secondary analyses on continuous glucose monitoring (CGM) using baseline observational data from three randomised controlled trials and assessed the relationship with established vascular markers. We used standard CGM summary statistics and principal component analysis to generate individual glucose variability signatures for each participant. Cluster analysis was then employed to establish three GV clusters (low, intermediate, or high GV, respectively). The relationship with thrombotic biomarkers was then investigated according to insulin resistance, assessed as estimated glucose disposal rate (eGDR). Results Of 107 patients, 45%, 37%, and 18% of patients were assigned into low, intermediate, and high GV clusters, respectively. Thrombosis biomarkers (including fibrinogen, plasminogen activator inhibitor-1, tissue factor activity, and tumour necrosis factor-alpha) increased in a stepwise fashion across all three GV clusters; this increase in thrombosis markers was evident in the presence of low but not high eGDR and at a threshold of eGDR <5.1 mg/kg/min. Conclusion Higher GV is associated with increased thrombotic biomarkers in type 1 diabetes but only in those with concomitant insulin resistance.","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48795923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis 2型糖尿病患者的降糖药和血糖变异性:一项系统综述和网络荟萃分析
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-05-01 DOI: 10.1177/14791641221106866
SuA Oh, Sujata Purja, Hocheol Shin, Minji Kim, Eunyoung Kim
While hemoglobin A1c (HbA1c) is commonly used to monitor therapy response in type 2 diabetes (T2D), GV is emerging as an essential additional metric for optimizing glycemic control. Our goal was to learn more about the impact of hypoglycemic agents on HbA1c levels and GV in patients with T2D. A systematic review and network meta-analysis (NMA) of randomized controlled trials were performed to assess the effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter (SGLT)-2 inhibitors, dipeptidyl peptidase (DPP)-4 inhibitors, sulfonylurea and thiazolidinediones on Mean Amplitude of Glycemic Excursions (MAGE) and HbA1c. Searches were performed using PubMed and EMBASE. A random-effect model was used in the NMA, and the surface under the cumulative ranking was used to rank comparisons. All studies were checked for quality according to their design and also for heterogeneity before inclusion in this NMA. The highest reduction in MAGE was achieved by GLP-1 RAs (SUCRA 0.83), followed by DPP-4 inhibitors (SUCRA: 0.72), and thiazolidinediones (SUCRA: 0.69). In terms of HbA1c reduction, GLP-1 RAs were the most effective (SUCRA 0.81), followed by DPP-4 inhibitors (SUCRA 0.72) and sulfonylurea (SUCRA 0.65). Our findings indicated that GLP-1 RAs have relatively high efficacy in terms of HbA1c and MAGE reduction when compared with other hypoglycemic agents and can thus have clinical application. Future studies with a larger sample size and appropriate subgroup analyses are warranted to completely understand the glycemic effects of these agents in various patients with T2D. The protocol for this systematic review was registered with the International Prospective Register of Systematic Reviews (CRD42021256363).
虽然糖化血红蛋白(HbA1c)通常用于监测2型糖尿病(T2D)的治疗反应,但GV正在成为优化血糖控制的重要附加指标。我们的目标是更多地了解降糖药对T2D患者HbA1c水平和GV的影响。对随机对照试验进行了系统回顾和网络荟萃分析(NMA),以评估胰高血糖素样肽1受体激动剂(GLP-1 RAs)、钠-葡萄糖共转运体(SGLT)-2抑制剂、二肽基肽酶(DPP)-4抑制剂、磺脲类和噻唑烷二酮类药物对血糖偏离平均幅度(MAGE)和HbA1c的影响。使用PubMed和EMBASE进行搜索。NMA采用随机效应模型,采用累积排序下的曲面进行排序比较。在纳入本NMA之前,所有研究均根据其设计进行质量检查和异质性检查。GLP-1 RAs (SUCRA: 0.83)实现了最大的MAGE降低,其次是DPP-4抑制剂(SUCRA: 0.72)和噻唑烷二酮类(SUCRA: 0.69)。在降低HbA1c方面,GLP-1 RAs最有效(SUCRA为0.81),其次是DPP-4抑制剂(SUCRA为0.72)和磺脲类(SUCRA为0.65)。我们的研究结果表明,与其他降糖药相比,GLP-1 RAs在降低HbA1c和MAGE方面具有较高的疗效,具有临床应用价值。未来的研究需要更大的样本量和适当的亚组分析,以完全了解这些药物对不同t2dm患者的降血糖作用。本系统评价的方案已在国际前瞻性系统评价注册(CRD42021256363)注册。
{"title":"Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis","authors":"SuA Oh, Sujata Purja, Hocheol Shin, Minji Kim, Eunyoung Kim","doi":"10.1177/14791641221106866","DOIUrl":"https://doi.org/10.1177/14791641221106866","url":null,"abstract":"While hemoglobin A1c (HbA1c) is commonly used to monitor therapy response in type 2 diabetes (T2D), GV is emerging as an essential additional metric for optimizing glycemic control. Our goal was to learn more about the impact of hypoglycemic agents on HbA1c levels and GV in patients with T2D. A systematic review and network meta-analysis (NMA) of randomized controlled trials were performed to assess the effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter (SGLT)-2 inhibitors, dipeptidyl peptidase (DPP)-4 inhibitors, sulfonylurea and thiazolidinediones on Mean Amplitude of Glycemic Excursions (MAGE) and HbA1c. Searches were performed using PubMed and EMBASE. A random-effect model was used in the NMA, and the surface under the cumulative ranking was used to rank comparisons. All studies were checked for quality according to their design and also for heterogeneity before inclusion in this NMA. The highest reduction in MAGE was achieved by GLP-1 RAs (SUCRA 0.83), followed by DPP-4 inhibitors (SUCRA: 0.72), and thiazolidinediones (SUCRA: 0.69). In terms of HbA1c reduction, GLP-1 RAs were the most effective (SUCRA 0.81), followed by DPP-4 inhibitors (SUCRA 0.72) and sulfonylurea (SUCRA 0.65). Our findings indicated that GLP-1 RAs have relatively high efficacy in terms of HbA1c and MAGE reduction when compared with other hypoglycemic agents and can thus have clinical application. Future studies with a larger sample size and appropriate subgroup analyses are warranted to completely understand the glycemic effects of these agents in various patients with T2D. The protocol for this systematic review was registered with the International Prospective Register of Systematic Reviews (CRD42021256363).","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43341846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The relationship between the elevation of haemoglobin A1c level, sleep quality and sleep duration in clinically diagnosed pre-diabetic patients in a nationally representative sample. 在全国具有代表性的临床诊断的糖尿病前期患者中,血红蛋白A1c水平升高与睡眠质量和睡眠时间的关系
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-01-01 DOI: 10.1177/14791641211067421
Lindsy Kass, Julia C Sanderson, Terun Desai, Rebecca Hurst

Background/objectives: Type 2 diabetes mellitus (T2DM) is one of the most common chronic illnesses in the United Kingdom accounting for approximately 15% of deaths per year. Growing evidence suggests that sleep duration and quality contributes towards this. This study aimed to determine whether there was a significant relationship between the elevation of haemoglobin A1c (HbA1c) level, sleep quality (SQ) and sleep duration (SD) in clinically diagnosed pre-diabetic patients.

Subjects/methods: Following referral from a relevant healthcare professional, participants (n = 40) were registered on the National Health Service England, funded Healthier You: National Diabetes Prevention Programme and completed a Pittsburgh Sleep Quality Index questionnaire to evaluate SQ and SD.

Results: A Spearman's correlation showed an association between HbA1c, SQ and SD measures. A simple linear regression showed a significant large positive association (rs = 0.913, p < 0.001) and significant regression (F (1) = 39, p < 0.001) with an R2 of 0.842 between HbA1c level and SQ. Additionally, a significant large negative association (rs = 0.757, p < 0.001) and significant regression was found (F (1) = 39, p < 0.001) with an R2 of 0.570 between HbA1c and SD.

Conclusions: This study suggests a relationship between SQ, SD and the elevation of HbA1c which may contribute towards prevalence of T2DM and may help to increase adherence to diabetes prevention programmes.

背景/目的:2型糖尿病(T2DM)是英国最常见的慢性疾病之一,每年约占死亡人数的15%。越来越多的证据表明,睡眠时间和睡眠质量与此有关。本研究旨在确定临床诊断的糖尿病前期患者血红蛋白A1c (HbA1c)水平升高与睡眠质量(SQ)和睡眠时间(SD)之间是否存在显著关系。受试者/方法:根据相关医疗保健专业人员的推荐,参与者(n = 40)在英国国家卫生服务中心注册,资助了“更健康的你:国家糖尿病预防计划”,并完成了匹兹堡睡眠质量指数问卷来评估SQ和SD。结果:Spearman相关性显示HbA1c、SQ和SD测量之间存在关联。简单线性回归分析显示HbA1c水平与SQ呈正相关(rs = 0.913, p < 0.001),显著回归分析(F (1) = 39, p < 0.001), R2为0.842。此外,HbA1c与SD之间存在显著的负相关(rs = 0.757, p < 0.001)和显著的回归(F (1) = 39, p < 0.001), R2为0.570。结论:本研究提示SQ、SD和HbA1c升高之间的关系,这可能有助于2型糖尿病的患病率,并可能有助于提高对糖尿病预防计划的依从性。
{"title":"The relationship between the elevation of haemoglobin A1c level, sleep quality and sleep duration in clinically diagnosed pre-diabetic patients in a nationally representative sample.","authors":"Lindsy Kass,&nbsp;Julia C Sanderson,&nbsp;Terun Desai,&nbsp;Rebecca Hurst","doi":"10.1177/14791641211067421","DOIUrl":"https://doi.org/10.1177/14791641211067421","url":null,"abstract":"<p><strong>Background/objectives: </strong>Type 2 diabetes mellitus (T2DM) is one of the most common chronic illnesses in the United Kingdom accounting for approximately 15% of deaths per year. Growing evidence suggests that sleep duration and quality contributes towards this. This study aimed to determine whether there was a significant relationship between the elevation of haemoglobin A1c (HbA1c) level, sleep quality (SQ) and sleep duration (SD) in clinically diagnosed pre-diabetic patients.</p><p><strong>Subjects/methods: </strong>Following referral from a relevant healthcare professional, participants (<i>n</i> = 40) were registered on the National Health Service England, funded Healthier You: National Diabetes Prevention Programme and completed a Pittsburgh Sleep Quality Index questionnaire to evaluate SQ and SD.</p><p><strong>Results: </strong>A Spearman's correlation showed an association between HbA1c, SQ and SD measures. A simple linear regression showed a significant large positive association (rs = 0.913, <i>p</i> < 0.001) and significant regression (F (1) = 39, <i>p</i> < 0.001) with an R2 of 0.842 between HbA1c level and SQ. Additionally, a significant large negative association (rs = 0.757, <i>p</i> < 0.001) and significant regression was found (F (1) = 39, <i>p</i> < 0.001) with an R2 of 0.570 between HbA1c and SD.</p><p><strong>Conclusions: </strong>This study suggests a relationship between SQ, SD and the elevation of HbA1c which may contribute towards prevalence of T2DM and may help to increase adherence to diabetes prevention programmes.</p>","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":"19 1","pages":"14791641211067421"},"PeriodicalIF":2.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39801255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Risk factors associated with mortality in individuals with type 2 diabetes following an episode of severe hypoglycaemia. Results from a randomised controlled trial. 2型糖尿病患者严重低血糖发作后死亡率的相关危险因素随机对照试验的结果。
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-01-01 DOI: 10.1177/14791641211067415
Sam M Pearson, Noppadol Kietsiriroje, Beverley Whittam, Rebecca J Birch, Matthew D Campbell, Ramzi A Ajjan

Background: Severe hypoglycaemia may pose significant risk to individuals with type 2 diabetes (T2D), and evidence surrounding strategies to mitigate this risk is lacking.

Methods: Data was re-analysed from a previous randomised controlled trial studying the impact of nurse-led intervention on mortality following severe hypoglycaemia in the community. A Cox-regression model was used to identify baseline characteristics associated with mortality and to adjust for differences between groups. Kaplan-Meier curves were created to demonstrate differences in outcome between groups across different variables.

Results: A total of 124 participants (mean age = 75, 56.5% male) were analysed. In univariate analysis, Diabetes Severity Score (DSS), age and insulin use were baseline factors found to correlate to mortality, while HbA1C and established cardiovascular disease showed no significant correlations. Hazard ratio favoured the intervention (0.68, 95% CI: 0.38-1.19) and in multivariate analysis, only DSS demonstrated a relationship with mortality. Comparison of Kaplan-Meier curves across study groups suggested the intervention is beneficial irrespective of HbA1c, diabetes severity score or age.

Conclusion: While DSS predicts mortality following severe community hypoglycaemia in individuals with T2D, a structured nurse-led intervention appears to reduce the risk of death across a range of baseline parameters.

背景:严重低血糖可能对2型糖尿病(T2D)患者构成重大风险,目前缺乏减轻这种风险的相关证据。方法:重新分析之前一项随机对照试验的数据,该试验研究了护士主导的干预对社区严重低血糖患者死亡率的影响。使用cox回归模型确定与死亡率相关的基线特征,并调整组间差异。Kaplan-Meier曲线的创建是为了证明不同变量组间结果的差异。结果:共分析124名参与者(平均年龄75岁,男性56.5%)。在单变量分析中,糖尿病严重程度评分(DSS)、年龄和胰岛素使用是与死亡率相关的基线因素,而HbA1C和已确定的心血管疾病没有显着相关性。风险比支持干预(0.68,95% CI: 0.38-1.19),在多变量分析中,只有DSS与死亡率相关。各组间Kaplan-Meier曲线的比较表明,无论HbA1c、糖尿病严重程度评分或年龄如何,干预都是有益的。结论:虽然DSS可以预测T2D患者发生严重社区低血糖后的死亡率,但在一系列基线参数中,由护士主导的结构化干预似乎可以降低死亡风险。
{"title":"Risk factors associated with mortality in individuals with type 2 diabetes following an episode of severe hypoglycaemia. Results from a randomised controlled trial.","authors":"Sam M Pearson,&nbsp;Noppadol Kietsiriroje,&nbsp;Beverley Whittam,&nbsp;Rebecca J Birch,&nbsp;Matthew D Campbell,&nbsp;Ramzi A Ajjan","doi":"10.1177/14791641211067415","DOIUrl":"https://doi.org/10.1177/14791641211067415","url":null,"abstract":"<p><strong>Background: </strong>Severe hypoglycaemia may pose significant risk to individuals with type 2 diabetes (T2D), and evidence surrounding strategies to mitigate this risk is lacking.</p><p><strong>Methods: </strong>Data was re-analysed from a previous randomised controlled trial studying the impact of nurse-led intervention on mortality following severe hypoglycaemia in the community. A Cox-regression model was used to identify baseline characteristics associated with mortality and to adjust for differences between groups. Kaplan-Meier curves were created to demonstrate differences in outcome between groups across different variables.</p><p><strong>Results: </strong>A total of 124 participants (mean age = 75, 56.5% male) were analysed. In univariate analysis, Diabetes Severity Score (DSS), age and insulin use were baseline factors found to correlate to mortality, while HbA1C and established cardiovascular disease showed no significant correlations. Hazard ratio favoured the intervention (0.68, 95% CI: 0.38-1.19) and in multivariate analysis, only DSS demonstrated a relationship with mortality. Comparison of Kaplan-Meier curves across study groups suggested the intervention is beneficial irrespective of HbA1c, diabetes severity score or age.</p><p><strong>Conclusion: </strong>While DSS predicts mortality following severe community hypoglycaemia in individuals with T2D, a structured nurse-led intervention appears to reduce the risk of death across a range of baseline parameters.</p>","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":"19 1","pages":"14791641211067415"},"PeriodicalIF":2.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39866466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Impact of prediabetes and duration of diabetes on radial artery atherosclerosis in acute coronary syndrome patients: An optical coherence tomography study. 糖尿病前期和糖尿病病程对急性冠状动脉综合征患者桡动脉粥样硬化的影响:一项光学相干断层扫描研究
IF 2.4 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-01-01 DOI: 10.1177/14791641221078108
Zixuan Li, Zhe Tang, Yujie Wang, Zijing Liu, Senhu Wang, Yuntao Wang, Guozhong Wang, Yuping Wang, Jincheng Guo

Background: Prediabetes (PDM) and diabetes mellitus (DM) are common among acute coronary syndrome (ACS) patients. The present study evaluated the association between diabetes status and radial artery (RA) atherosclerosis using optical coherence tomography (OCT) in ACS patients.

Methods: A total of 335 ACS patients who underwent RA OCT were categorized into the DM group, the PDM group, and the normal glucose metabolism (NGM) group. OCT characteristics and clinical variables were compared.

Results: RA atherosclerotic plaques were more frequent in the PDM and DM groups than in the NGM group (38.7% vs. 33.3% vs. 16.1%, p = 0.001). Lipid and calcified plaque occurrence were significantly more common in the DM group, followed by the PDM and NGM groups (19.3% vs. 14.6% vs. 6.5%, p = 0.027; 11.8% vs. 6.5% vs. 1.1%, p = 0.009). The prevalence of microvessels in the PDM group was significantly higher (42.7% vs 23.7%, p = 0.017) than in the NGM group but was comparable to the DM group. Multivariate analysis revealed that HbA1c level and age were independent predictors of RA plaque formation and eccentric intimal hyperplasia (all p<0.05).

Conclusions: RA atherosclerosis characteristics differ according to diabetes status. HbA1c level could be a useful marker for RA atherosclerosis progression in ACS patients.

背景:前驱糖尿病(PDM)和糖尿病(DM)在急性冠脉综合征(ACS)患者中很常见。本研究利用光学相干断层扫描(OCT)评估ACS患者的糖尿病状态与桡动脉粥样硬化之间的关系。方法:335例ACS患者行RA OCT分为DM组、PDM组和正常糖代谢组。比较OCT特征和临床指标。结果:PDM组和DM组RA动脉粥样硬化斑块发生率高于NGM组(38.7% vs. 33.3% vs. 16.1%, p = 0.001)。脂质斑块和钙化斑块在DM组更为常见,其次是PDM组和NGM组(19.3% vs. 14.6% vs. 6.5%, p = 0.027;11.8%比6.5%比1.1%,p = 0.009)。PDM组微血管患病率显著高于NGM组(42.7% vs 23.7%, p = 0.017),但与DM组相当。多因素分析显示,HbA1c水平和年龄是RA斑块形成和偏心内膜增生的独立预测因素。结论:RA动脉粥样硬化特征因糖尿病状态而异。HbA1c水平可能是ACS患者RA动脉粥样硬化进展的有用标志。
{"title":"Impact of prediabetes and duration of diabetes on radial artery atherosclerosis in acute coronary syndrome patients: An optical coherence tomography study.","authors":"Zixuan Li,&nbsp;Zhe Tang,&nbsp;Yujie Wang,&nbsp;Zijing Liu,&nbsp;Senhu Wang,&nbsp;Yuntao Wang,&nbsp;Guozhong Wang,&nbsp;Yuping Wang,&nbsp;Jincheng Guo","doi":"10.1177/14791641221078108","DOIUrl":"https://doi.org/10.1177/14791641221078108","url":null,"abstract":"<p><strong>Background: </strong>Prediabetes (PDM) and diabetes mellitus (DM) are common among acute coronary syndrome (ACS) patients. The present study evaluated the association between diabetes status and radial artery (RA) atherosclerosis using optical coherence tomography (OCT) in ACS patients.</p><p><strong>Methods: </strong>A total of 335 ACS patients who underwent RA OCT were categorized into the DM group, the PDM group, and the normal glucose metabolism (NGM) group. OCT characteristics and clinical variables were compared.</p><p><strong>Results: </strong>RA atherosclerotic plaques were more frequent in the PDM and DM groups than in the NGM group (38.7% vs. 33.3% vs. 16.1%, <i>p</i> = 0.001). Lipid and calcified plaque occurrence were significantly more common in the DM group, followed by the PDM and NGM groups (19.3% vs. 14.6% vs. 6.5%, <i>p</i> = 0.027; 11.8% vs. 6.5% vs. 1.1%, <i>p</i> = 0.009). The prevalence of microvessels in the PDM group was significantly higher (42.7% vs 23.7%, <i>p</i> = 0.017) than in the NGM group but was comparable to the DM group. Multivariate analysis revealed that HbA1c level and age were independent predictors of RA plaque formation and eccentric intimal hyperplasia (all <i>p</i><0.05).</p><p><strong>Conclusions: </strong>RA atherosclerosis characteristics differ according to diabetes status. HbA1c level could be a useful marker for RA atherosclerosis progression in ACS patients.</p>","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":"19 1","pages":"14791641221078108"},"PeriodicalIF":2.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/d5/10.1177_14791641221078108.PMC8866250.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39938427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Diabetes & Vascular Disease Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1